Multidrug Resistance Acinetobacter Bacteremia Secondary to Ventilator-Associated Pneumonia: Risk Factors and Outcome

Abstract

Purpose:

Acinetobacter baumannii is a multidrug resistant (MDR), gram-negative bacterium commonly implicated in ventilator-associated pneumonia (VAP) in critically ill patients. Patients in the intensive care unit (ICU) with VAP often subsequently develop A baumannii bacteremia, which may significantly worsen outcomes.

Materials and Methods:

In this study, we retrospectively reviewed the clinical and laboratory records of 129 ICU patients spanning 6 years with MDR A baumannii VAP; 46 (35%) of these patients had concomitant MDR A baumannii bacteremia.

Results:

The ICU mortality rate was higher in patients with VAP having A baumannii bacteremia compared to nonbacteremic patients (32.4% vs 9.6% respectively, P < .005). Age >65 years, an Acute Physiology and Chronic Health Evaluation II (APACHE-II) score higher than 20, a Sequential Organ Failure Assessment (SOFA) score higher than 7 on the day of bacteremia, and the presence of comorbid disease (chronic obstructive pulmonary disease [COPD] and chronic renal failure) were found to be independent risk factors for in-hospital mortality in this population. Multidrug resistant A baumannii was not an independent risk factor for mortality.

Conclusion:

Although the presence of comorbid diseases (COPD and chronic renal failure) and severity of disease (APACHE > 20 and SOFA >7) were found to be independent risk factors for ICU mortality, MDR A baumannii bacteremia was not an independent risk factor for mortality in our critically ill population.

Keywords

multidrug resistant Acinetobacter VAP multidrug resistant Acinetobacter bacteremia risk factor outcome

Get full access to this article

View all access options for this article.

References

Safdar

Dezfulian

Collard

Saint

. Clinical and economic consequences of ventilator-associated pneumonia: a systematic review. Crit Care Med. 2005;33(10):2184–2193.

Behnia

Logan

Fallen

Catalano

. Nosocomial and ventilator-associated pneumonia in a community hospital intensive care unit: a retrospective review and analysis. BMC Res Notes. 2014;7:232.

Siempos

Vardakas

Kyriakopoulos

Ntaidou

Falagas

. Predictors of mortality in adult patients with ventilator-associated pneumonia: a meta-analysis. Shock. 2010;33(6):590–601.

Garnacho-Montero

Ortiz-Leyba

Fernandez-Hinojosa

. Acinetobacter baumannii ventilator-associated pneumonia: epidemiological and clinical findings. Intensive Care Med. 2005;31(5):649–655.

DeRyke

Lodise

Jr Rybak

McKinnon

. Epidemiology, treatment, and outcomes of nosocomial bacteremic staphylococcus aureus pneumonia. Chest. 2005;128(3):1414–1422.

Gonzalez

Rubio

Romero-Vivas

Gonzalez

Picazo

. Staphylococcus aureus bacteremic pneumonia: differences between community and nosocomial acquisition. Int J Infect Dis. 2003;7(2):102–108.

Kerdudou

Laschke

Sinha

Preissner

Menger

Herrmann

. Fibronectin binding proteins contribute to the adherence of staphylococcus aureus to intact endothelium in vivo. Thromb Haemost. 2006;96(2):183–189.

Routsi

Pratikaki

Platsouka

. Carbapenem-resistant versus carbapenem-susceptible acinetobacter baumannii bacteremia in a greek intensive care unit: Risk factors, clinical features and outcomes. Infection. 2010;38(3):173–180.

Knaus

Draper

Wagner

Zimmerman

. Apache II: a severity of disease classification system. Crit Care Med. 1985;13(10):818–829.

10.

Vincent

Moreno

Takala

. The sofa (sepsis-related organ failure assessment) score to describe organ dysfunction/failure. On behalf of the working group on sepsis-related problems of the european society of intensive care medicine. Intensive Care Med. 1996;22(7):707–710.

11.

Bernard

Artigas

Brigham

. Report of the american-european consensus conference on ards: Definitions, mechanisms, relevant outcomes and clinical trial coordination. The consensus committee. Intensive Care Med. 1994;20(3):225–232.

12.

American Thoracic Society; Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005;171(4):388–416.

13.

Beardsley

Williamson

Johnson

Ohl

Karchmer

Bowton

. Using local microbiologic data to develop institution-specific guidelines for the treatment of hospital-acquired pneumonia. Chest. 2006;130(3):787–793.

14.

Tsakiridou

Makris

Daniil

. Acinetobacter baumannii infection in prior icu bed occupants is an independent risk factor for subsequent cases of ventilator-associated pneumonia. Biomed Res Int. 2014;2014:193516.

15.

Lee

Chen

Huang

Chiu

. Risk factors and outcome analysis of acinetobacter baumannii complex bacteremia in critical patients. Crit Care Med. 2014;42(5):1081–1088.

16.

Gursel

Aydogdu

Ozyilmaz

Ozis

. Risk factors for treatment failure in patients with ventilator-associated pneumonia receiving appropriate antibiotic therapy. J Crit Care. 2008;23(1):34–40.

17.

Magret

Lisboa

Martin-Loeches

. Bacteremia is an independent risk factor for mortality in nosocomial pneumonia: a prospective and observational multicenter study. Crit Care. 2011;15(1):r62.

18.

Agbaht

Diaz

Munoz

. Bacteremia in patients with ventilator-associated pneumonia is associated with increased mortality: a study comparing bacteremic vs. nonbacteremic ventilator-associated pneumonia. Crit Care Med. 2007;35(9):2064–2070.

19.

Wisplinghoff

Bischoff

Tallent

Seifert

Wenzel

Edmond

. Nosocomial bloodstream infections in us hospitals: Analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis. 2004;39(3):309–317.

20.

Chuang

Sheng

. Influence of genospecies of acinetobacter baumannii complex on clinical outcomes of patients with acinetobacter bacteremia. Clin Infect Dis. 2011;52(3):352–360.